-

Agilent Names Bret DiMarco Chief Legal Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Bret DiMarco has been named to lead the company’s global legal organization as senior vice president and chief legal officer, as well as serving as secretary. He begins his new role with Agilent effective today.

“Bret DiMarco is another outstanding addition to the Agilent leadership team,” said Padraig McDonnell, Agilent president and CEO. “Bret’s broad range of tactical and strategic experience across a variety of industries will be valuable assets as our company becomes even more customer focused and even more nimble to continue to win in the marketplace and add value to customers and shareholders.”

Most recently, DiMarco served as chief legal officer of Pendo.io, a leading global venture-backed software-as-a-service (SaaS) company. Before joining Pendo.io, he was executive vice president, chief legal officer, and corporate secretary for Coherent Inc., a multinational corporation and one of the world’s largest laser manufacturers. There, he was responsible for all legal matters, the company’s intellectual property program and global trade compliance. After leading the process for the sale and closing of the company’s merger with II-VI Incorporated, he served as a special adviser to the company president during the initial transition period.

DiMarco previously was an associate and member of the international law firm Wilson Sonsini Goodrich & Rosati, where his practice focused on corporate and securities law, corporate governance and mergers and acquisitions. DiMarco also has served on multiple Nasdaq councils, currently as the chair of the Nasdaq Exchange Nominating Committee. He has been an adjunct assistant professor of law at the University of California Law School, San Francisco since 2004.

DiMarco is a graduate of the University of Southern California Law School and received his bachelor’s degree from the University of California, Irvine.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Sarah Litton
+1 408-361-0405
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact:
Sarah Litton
+1 408-361-0405
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom